# Zhi Yang

> Zhi Yang is a Series A investor at BVCF (Shanghai) backing Biotechnology and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BVCF](https://shizune.co/investors/profile/bioveda-china-fund)
- Location: Shanghai, China
- Total investments: 6
- Last investment: Apr 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/zhi-yang-950b116

Zhi Yang is a Series A investor at BVCF in Shanghai focused on Biotechnology and Medical. Zhi Yang founded BVCF in 2005. He has over 16 years of China and U.S. life sciences investment experience, with a total of over 20 years in the life sciences industry as a private equity investor, venture capital investor, senior executive, entrepreneur, and scientific inventor.As private equity and venture capital investor, he has builtportfolios of 25 companies, with 8 exits (4 IPO, 4 acquisitions). As entrepreneur, he co-founded 7 companies, 6 of which continue to conduct business and grow. As scientist, he was the principal inventor of more than 10 U.S. and international patents, which have been documented to have earned MNC’s over $250 million.He was a senior fellow and faculty member at Rockefeller University and is now an advisor to the China Health and Medical Development Foundation, under China’s Ministry of Health.Yang earned his PhD in Molecular Biology and Biochemistry, as well as an M.A. in Cellular and Developmental Biology, both from Harvard University. As a fellow of CUSBEA’s first class, the first group of mainland Chinese biology scholars selected to be brought to the U.S. after China opened its doors in 1979.From 1982-1989, the CUSBEA program, selected 422 of China’s brightest scholars and placed them in top U.S. universities for biology study. Today, as when they left China, the CUSBEA Fellows are respected as a pioneering and intellectually elite force for progress in China’s life sciences.Yang is currently an advisor to the China Health and Medical Development Foundation, under China’s Ministry of Health.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Medical | 3 | 50% |
| Health Care | 3 | 50% |
| Pharmaceutical | 2 | 33% |
| Beauty | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 67% |
| Seed | 1 | 17% |
| Series C | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| China | 2 | 33% |
| Iceland | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Qiselian Biotechnology | Qiselian Biotech focuses on personalized cell therapy and anti-aging. Based on the new generation of induced pluripotent stem cell (iPSC) technology, it develops innovative products and services for autologous cell therapy, regenerative medicine and health management. |  | Seed | Apr 18, 2025 |  |
| Cellenkos | Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. | $15M | Series A | Nov 04, 2021 |  |
| Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M | Series C | May 04, 2021 |  |
| CARsgen Therapeutics | CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, bycompleting World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. |  | Series A |  |  |
| Jaguar Health | Jaguar Health develops and commercializes plant-based prescription medicines that target gastrointestinal distress in humans and animals. Its human health activities include prescription drugs derived from botanical sources for symptoms like chronic diarrhea, and it supports research into expanded uses of its lead compounds through clinicalprograms. The company’s animal health efforts involve prescription therapies for gastrointestinal conditions in companion animals, including products conditionally approved for veterinary use. Jaguar Health also pursues partnerships and joint ventures to explore additional plant-derived medicines, and it manages sustainable sourcing programs for its botanical ingredients. | $6.8M | Series A |  |  |
| DiaCarta | DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix.DiaCarta supplies precise molecular diagnostic cancer assays that enable the mostsensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research. | $8M | Series A |  |  |

6 of 6 investments shown.

## Co-investors
- [Hyfinity Investments](https://shizune.co/investors/profile/hyfinity-investments) — VC Fund, 2 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 1 deal together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 1 deal together
- [Innovation and Technology Venture Fund](https://shizune.co/investors/profile/innovation-and-technology-venture-fund) — VC Fund, 1 deal together
- [Nan Fung Life Sciences](https://shizune.co/investors/profile/nan-fung-life-sciences) — VC Fund, 1 deal together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 1 deal together

## About BVCF

VC Fund · Shanghai, China

In 2005, Bvcf Became The First International Private Equity Firm To Come To China Dedicated To Investing In China'S Life Sciences. Dr. Zhi Yang Founded The Firm With The Vision That It Would Be The Key Investor In China'S Life Sciences Golden Age By Being First And Bringing Unmatched Domain Expertise.

2 contacts available at BVCF.

| Name | Title | Profile |
| --- | --- | --- |
| Zhi Yang | Founder & Managing Partner | https://shizune.co/investors/profile/zhi-yang |
| Mengqi Chen | CFO | https://shizune.co/investors/profile/mengqi-chen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Zhi Yang invest in?

Zhi Yang invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Zhi Yang last invest?

The most recent investment recorded for Zhi Yang closed in Apr 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co